Literature DB >> 7490724

N-[(1-butyl-4-piperidinyl)methyl]-3,4dihydro-2H-[1,3]oxazino[3,2- a]indole10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity.

L M Gaster1, G F Joiner, F D King, P A Wyman, J M Sutton, S Bingham, E S Ellis, G J Sanger, K A Wardle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7490724     DOI： 10.1021/jm00024a002

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  7 in total

1.  Comparative receptor mapping of serotoninergic 5-HT3 and 5-HT4 binding sites.

Authors:  M L López-Rodríguez; M J Morcillo; B Benhamú; M L Rosado
Journal:  J Comput Aided Mol Des       Date:  1997-11       Impact factor: 3.686

2.  Selective and functional 5-hydroxytryptamine4 receptor antagonism by SB 207266.

Authors:  K A Wardle; S Bingham; E S Ellis; L M Gaster; B Rushant; M I Smith; G J Sanger
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

3.  Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle.

Authors:  B Darblade; D Behr-Roussel; D Gorny; T Lebret; G Benoit; J-P Hieble; D Brooks; L Alexandre; F Giuliano
Journal:  World J Urol       Date:  2005-05-18       Impact factor: 4.226

4.  Effects of treatment with a 5-HT4 receptor antagonist in heart failure.

Authors:  J A K Birkeland; I Sjaastad; T Brattelid; E Qvigstad; E R Moberg; K A Krobert; R Bjørnerheim; T Skomedal; O M Sejersted; J-B Osnes; F O Levy
Journal:  Br J Pharmacol       Date:  2006-12-11       Impact factor: 8.739

5.  The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.

Authors:  D T Beattie; J A M Smith; D Marquess; R G Vickery; S R Armstrong; T Pulido-Rios; J L McCullough; C Sandlund; C Richardson; N Mai; P P A Humphrey
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

6.  The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.

Authors:  D T Beattie; S R Armstrong; J P Shaw; D Marquess; C Sandlund; J A M Smith; J A Taylor; P P A Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-12       Impact factor: 3.000

7.  The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties.

Authors:  David T Beattie; Scott R Armstrong; Ross G Vickery; Pamela R Tsuruda; Christina B Campbell; Carrie Richardson; Julia L McCullough; Oranee Daniels; Kathryn Kersey; Yu-Ping Li; Karl H S Kim
Journal:  Front Pharmacol       Date:  2011-05-30       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.